Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 5.67Suven Life Sciences exhibits a mixed financial profile. The company shows very strong solvency and liquidity, indicating a robust ability to meet its obligations. However, profitability metrics are significantly negative, raising concerns about the firm's ability to generate profits from its operations. Growth metrics are highly variable, with strong EPS and operating profit growth offset by declines in revenue and assets. Efficiency ratios are also mixed, with high inventory turnover but low fixed asset and capital turnover. These factors suggest potential challenges in asset utilization and revenue generation. The absence of dividend payouts and negative interest coverage further contribute to a cautious outlook. Overall, while the company demonstrates financial stability, substantial improvements in profitability and revenue generation are necessary for sustained success.
Health Score : 5.67Suven Life Sciences exhibits a mixed financial profile. The company shows very strong solvency and liquidity, indicating a robust ability to meet its obligations. However, profitability metrics are significantly negative, raising concerns about the firm's ability to generate profits from its operations. Growth metrics are highly variable, with strong EPS and operating profit growth offset by declines in revenue and assets. Efficiency ratios are also mixed, with high inventory turnover but low fixed asset and capital turnover. These factors suggest potential challenges in asset utilization and revenue generation. The absence of dividend payouts and negative interest coverage further contribute to a cautious outlook. Overall, while the company demonstrates financial stability, substantial improvements in profitability and revenue generation are necessary for sustained success.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-183.46
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
-36.41
P/B RATIO
17.04
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
1439.18
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-36.13
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹381.6 as on Sep 1, 2026.
Growth Score : 7.20The company's growth ratios present a mixed outlook. While operating profit and EPS growth are strong, indicating improved profitability, revenue and asset growth are declining, suggesting potential challenges in expanding the company's top line and asset base. Net income growth is also robust, supporting the positive trend in profitability. This mixed performance suggests that the company is becoming more profitable but facing challenges in overall expansion.
Revenue Growth RatePoorOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RatePoorNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -7.69 | 16.67 | -14.29 | -41.67 | 0 |
| Operating Profit Growth Rate | -52.5 | -3.28 | -1.59 | -29.69 | -71.08 |
| Earnings Per Share (EPS) Growth | -47.88 | 3.04 | 11.07 | -52.9 | -42.2 |
| Asset Growth Rate | -15.62 | 260.19 | -26.74 | -52.63 | 362.22 |
| Net Income Growth Rate | -69.44 | 3.28 | 11.02 | -53.33 | -71.43 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medi Assist Healthcare Services Ltd | 8.17 | 28.70 | Neutral | 175.00 | 6.96 | 89.00 |
| 2 | Entero Healthcare Solutions Ltd | 6.94 | 68.27 | Neutral | 266.00 | 6.18 | 146.00 |
| 3 | Krsnaa Diagnostics Ltd | 6.17 | 17.91 | Neutral | 212.00 | 31.65 | 101.00 |
| 4 | Suven Life Sciences Ltd | 5.67 | -36.41 | Neutral | -284.00 | -2.08 | -276.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤13th Aug 25
Q1 FY26 Earnings Conference Call Transcript
NEUTRAL SENTIMENT
Suven Life Sciences Ltd. (SUVEN) is an Indian biopharmaceutical company primarily focused on the discovery and development of Novel Chemical Entities (NCEs) for Central Nervous System (CNS) disorders, particularly Alzheimer's and Parkinson's disease. While previously involved in Contract Research and Manufacturing Services (CRAMS) for commercial products, its core emphasis post-demerger is on its proprietary drug pipeline, funded partly by CRAMS for drug discovery.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Suven Life Sciences Ltd's P/E ratio (TTM) is -183.46, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Suven Life Sciences Ltd's P/B ratio is 17.04, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Suven Life Sciences Ltd's P/S ratio is 1439.18, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Suven Life Sciences Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Suven Life Sciences Ltd's EV/EBITDA ratio is -36.13.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Suven Life Sciences Ltd's ROE is -46.70%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Suven Life Sciences Ltd's ROA is -45.51%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Suven Life Sciences Ltd's ROCE is -77%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Suven Life Sciences Ltd's operating margin is -4057.14%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Suven Life Sciences Ltd's net margin is -3942.86%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Suven Life Sciences Ltd's current ratio is 22.94.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Suven Life Sciences Ltd's debt-to-equity ratio is 0.03.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Suven Life Sciences Ltd's interest coverage ratio is -121.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Suven Life Sciences Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Suven Life Sciences Ltd's EPS is -42.20.
(Source line: "Ratios as of 07 Oct 2026, based on last traded price of ₹381.60. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1989
Headquarters: Hyderabad, Telangana
Core Offerings: NCE drug discovery & development, Pre-clinical & clinical trials for NCEs, Contract Research and Manufacturing Services (CRAMS)
Stock Listing: NSE (SUVEN), BSE (530239)
Promoter: Jasti Group / Mr. Venkat Jasti
Founded in 1989 as Suven Life Sciences Ltd., the company initially established a Contract Research and Manufacturing Services (CRAMS) facility in 1995. Beginning in the early 2000s, Suven diversified its focus into Novel Chemical Entities (NCEs) discovery, primarily targeting CNS disorders, advancing several candidates into clinical trials throughout the 2010s. A significant milestone was the demerger of its commercial CRAMS business into Suven Pharmaceuticals Ltd. in 2020, with Suven Life Sciences Ltd. retaining the NCE pipeline and contract research services supporting its drug discovery efforts.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Contract Research and Manufacturing Services (CRAMS) | 100% | N/A (EBITDA is largely offset by R&D costs for NCEs) |
Contract Research and Manufacturing Services (CRAMS): This segment provides contract research and manufacturing support, primarily to innovator pharmaceutical companies for their drug discovery and development programs. The revenue generated from this segment helps to fund the company's proprietary NCE pipeline.
Novel Chemical Entities (NCEs) Discovery and Development: While not a revenue-generating segment in the traditional sense, this is the company's strategic core, focusing on the discovery, pre-clinical, and clinical development of proprietary drug candidates for unmet medical needs in CNS disorders.
Mr. Venkat Jasti - Chairman & CEO: Founder of Suven Life Sciences, he is the driving force behind the company's strategic vision and its pioneering efforts in NCE drug discovery for CNS disorders. He possesses extensive experience in pharmaceutical R&D and business development.
Suven Life Sciences Inc (USA)
Suven Neurosciences Inc (USA)
The most significant corporate action was the demerger of its Contract Development and Manufacturing Organisation (CDMO) business into Suven Pharmaceuticals Ltd. in 2020, with shareholders receiving 1 equity share of Suven Pharmaceuticals Ltd. for every 1 equity share of Suven Life Sciences Ltd. The company also executed a 1:1 bonus issue in 2015.
The Suven Life Sciences Ltd share price today is ₹381.60 on NSE (SUVEN), as of 14 Oct 2026.
As of 07 Oct 2026, Suven Life Sciences Ltd share price is ₹381.60, with previous close ₹381.60. Today's range is ₹381.60 to ₹381.60. The 52-week range is ₹124.11 to ₹395.40.
As of today, Suven Life Sciences Ltd's market cap is ₹10,074.24 crore (Mid Cap).
Suven Life Sciences Ltd's current P/E ratio is -183.46, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 33.
Suven Life Sciences Ltd's current P/B ratio is 17.04.
Suven Life Sciences Ltd's current dividend yield is N/A. Last dividend of ₹0.50 per share was declared on 20-Sep-2023.
Suven Life Sciences Ltd's EPS (TTM) is ₹-42.20.
Suven Life Sciences Ltd. (SUVEN) is an Indian biopharmaceutical company primarily focused on the discovery and development of Novel Chemical Entities (NCEs) for Central Nervous System (CNS) disorders, particularly Alzheimer's and Parkinson's disease. While previously involved in Contract Research and Manufacturing Services (CRAMS) for commercial products, its core emphasis post-demerger is on its proprietary drug pipeline, funded partly by CRAMS for drug discovery.
Suven Life Sciences Ltd is promoted by Jasti Group / Mr. Venkat Jasti, holding 70.15% as of 07 Oct 2026.
Suven Life Sciences Ltd is listed on NSE (SUVEN) and BSE (530239). Its next quarterly results are expected on August 2024.
Receivables Turnover Ratio
